Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

NCT03763370 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)
DRUG: Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)

Sponsor

GlaxoSmithKline